Samsung Bioepis

News

Cheaper Soliris biosimilars reach the US market

The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand.

News

Italy starts probe into Lucentis biosimilar delay allegation

Italy’s antitrust authority has launched an investigation against eight pharma companies, including Novartis and Roche, over suspicion they may have colluded to delay the

News

Samsung seeks 'interchangeable' label for Humira biosimilar

While there are already a number of biosimilars of AbbVie's big-selling Humira on the US market, so far, only one – Boehringer Ingelheim's

News

So it begins: Next Humira biosimilars launch in US

This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the

News

Pressure rises on Lucentis, as Coherus biosimilar gets FDA n...

The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be ful

News